Company intelligence / Profile preview
Marengo Therapeutics
Cambridge, MA, United Statesmarengotx.com ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Phase 1
01
Overview
Marengo Therapeutics has reported encouraging single-agent anti-tumor activity from its lead asset invikafusp alfa (STAR0602), particularly in PD1-resistant "cold" tumors. The FDA granted Fast Track designation to invikafusp alfa for treatment of tumor mutational burden-high colorectal cancer based on first-in-human Phase I results. The company’s approach leverages biomarker-driven trial design and focuses on durable immune responses by activating specific subsets of the human T-cell repertoire. Combination trials with Gilead's Trodelvy are ongoing/planned.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Antibody fusion proteins (e.g., T-cell activators and engagers)Bispecific antibodiesTrispecific antibodies
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Gilead Sciences – collaboration to combine invikafusp alfa with Trodelvy in advanced solid tumor trials[6].University of Pennsylvania Institute for Immunology and Immune Health / Dr. E John Wherry – multi-year research collaboration focused on mechanism-of-action studies and expansion into autoimmunity using the MSTAR platform[10].King’s College London – immuno-oncology research collaboration involving STAR0602 development/preclinicals [9].
Beyond the preview
Go deeper on Marengo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marengo Therapeutics.